Your browser doesn't support javascript.
loading
Impact of Cancer, Inflammation, and No Standard Risk Factors in Patients With Myocardial Infarction.
Yaginuma, Hiroaki; Saito, Yuichi; Goto, Hiroki; Asada, Kazunari; Shiko, Yuki; Sato, Takanori; Hashimoto, Osamu; Kitahara, Hideki; Kobayashi, Yoshio.
Afiliação
  • Yaginuma H; Department of Cardiovascular Medicine, Chiba University Hospital, Chiba, Japan.
  • Saito Y; Department of Cardiovascular Medicine, Chiba University Hospital, Chiba, Japan.
  • Goto H; Department of Cardiovascular Medicine, Chiba University Hospital, Chiba, Japan.
  • Asada K; Department of Cardiovascular Medicine, Chiba University Hospital, Chiba, Japan.
  • Shiko Y; Biostatistics Section, Clinical Research Center, Chiba University Hospital, Chiba, Japan.
  • Sato T; Department of Cardiovascular Medicine, Chiba University Hospital, Chiba, Japan.
  • Hashimoto O; Department of Cardiology, Chiba Emergency and Psychiatric Medical Center, Chiba, Japan.
  • Kitahara H; Department of Cardiovascular Medicine, Chiba University Hospital, Chiba, Japan.
  • Kobayashi Y; Department of Cardiovascular Medicine, Chiba University Hospital, Chiba, Japan.
JACC Asia ; 4(7): 507-516, 2024 Jul.
Article em En | MEDLINE | ID: mdl-39101117
ABSTRACT

Background:

The lack of standard modifiable cardiovascular risk factors (SMuRFs), including hypertension, diabetes, dyslipidemia, and smoking, is reportedly associated with poor outcomes in acute myocardial infarction (AMI). Among patients with no SMuRFs, cancer and chronic systemic inflammatory diseases (CSIDs) may be major etiologies of AMI.

Objectives:

The purpose of this study was to evaluate clinical characteristics and outcomes of patients with cancer, CSIDs, and no SMuRFs in AMI.

Methods:

This multicenter registry included 2,480 patients with AMI undergoing percutaneous coronary intervention. Patients were divided into 4 groups active cancer, CSIDs, no SMuRFs, and those remaining. The coprimary endpoint was major adverse cardiovascular events (MACE) and major bleeding events, during hospitalization and after discharge.

Results:

Of 2,480 patients, 104 (4.2%), 94 (3.8%), and 120 (4.8%) were grouped as cancer, CSIDs, and no SMuRFs, respectively. During the hospitalization, MACE rates were highest in the no SMuRFs group, followed by the cancer, CSIDs, and SMuRFs groups (22.5% vs 15.4% vs 12.8% vs 10.2%; P < 0.001), whereas bleeding risks were highest in the cancer group, followed by the no SMuRFs, CSIDs, and SMuRFs groups (15.4% vs 10.8% vs 7.5% vs 4.9%; P < 0.001). After discharge, the rates of MACE (33.3% vs 22.7% vs 11.3% vs 9.2%; P < 0.001) and bleeding events (8.6% vs 6.7% vs 3.8% vs 2.9%; P = 0.01) were higher in the cancer group than in the CSIDs, no SMuRFs, and SMuRFs groups.

Conclusions:

Patients with active cancer, CSIDs, and no SMuRFs differently had worse outcomes after AMI in ischemic and bleeding endpoints during hospitalization and/or after discharge, compared with those with SMuRFs.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: JACC Asia Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: JACC Asia Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão País de publicação: Estados Unidos